Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2024 09:00 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
February 28, 2019 09:15 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Featured on CBS in San Francisco

CHARLOTTESVILLE, Va., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
February 26, 2019 08:00 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option

Proceeds from Offering Expected to Fully Fund Initial Phase 3 Trial of AD04 CHARLOTTESVILLE, Va., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage...
February 21, 2019 08:45 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

CHARLOTTESVILLE, Va., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for...
February 20, 2019 09:00 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial

CHARLOTTESVILLE, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of...
February 15, 2019 08:30 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse

Continuation patent would allow for broader protection beyond claims protected under current patents CHARLOTTESVILLE, Va., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
February 12, 2019 09:33 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

Distinguished Professor Markus Heilig joins an accomplished assemblage of addiction specialists including Dr. Giovanni Addolorato and Professors Hannu Alho, Tomas Zima and Sebastian Mueller ...
February 07, 2019 09:15 ET | Source: Adial Pharmaceuticals, Inc.

Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award

Dr. Johnson Recognized for Advancing Scientific Understanding of Alcoholism and its Prevention CHARLOTTESVILLE, Va., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;...
February 01, 2019 09:20 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder

Scheduled to appear today on KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT Additional appearance scheduled on KPIX-TV (CBS-CW) “Bay Area Focus” morning show February 3rd during...
January 24, 2019 08:30 ET | Source: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants

Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 CHARLOTTESVILLE, Va., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW)...

Next Page keyboard_arrow_right